{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:51:00Z","timestamp":1790913060945,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:p>The use of neoadjuvant chemotherapy (NAC) as a first-line therapy for advanced high-grade serous ovarian carcinoma (HGSOC) has increased. However, several studies have reported NAC-induced platinum resistance. This study aimed to evaluate the predictive impact of clinical factors on chemotherapy response score (CRS) and to select patients who would respond well to NAC. This multicenter retrospective (study included patients treated between January 2016 and December 2021). International Federation of Gynecology and Obstetrics stage IIIC and IV HGSOC patients were eligible. Institutionally strict complete resectability criteria were used in the present study. Pathological slides were scored according to the CRS criteria. Among 172 patients with HGSOC, 87 (50.6%) had stage IIIC disease and 85 (49.4%) had stage IV disease. And 35 (20.4%) had CRS1, 103 patients were CRS2 (59.9%), and 34 patients were CRS3 (19.7%). Compared with CRS1, simultaneous metastases to distant lymph nodes and solid organs confirmed by imaging were associated with a 75% reduction in CRS2 (odds ratio\u2005=\u20050.25; 95% confidence interval: 0.09\u20130.70; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.008). And breast cancer susceptibility gene 1\/2 mutation was positively (odds ratio\u2005=\u20058.41; 95% confidence interval: 2.25\u201331.52; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.002) associated with CRS3 compared to CRS1. Patients with CRS3 had significantly longer progression-free survival (PFS), with median PFS of 9.8, 14.8, and 27.0 months for CRS of 1, 2, and 3, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). Overall survival was also prolonged in patients with CRS3 (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001). Germline breast cancer susceptibility gene 1\/2 mutation was a predictor of CRS3 and a good prognostic factor for the survival rate. Simultaneous metastasis to distant lymph nodes and solid organs is a predictor of CRS1. CRS inversely correlated with PFS and overall survival.<\/jats:p>","DOI":"10.1097\/md.0000000000040487","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T20:01:30Z","timestamp":1732564890000},"page":"e40487","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Predictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score"],"prefix":"10.1097","volume":"103","author":[{"given":"Mia","family":"Park","sequence":"first","affiliation":[{"name":"Department of Obstetrics & Gynecology, Chungnam National University Hospital, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Kyo","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Chungnam National University Sejong Hospital, Sejong, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myong Cheol","family":"Lim","sequence":"additional","affiliation":[{"name":"Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Yoon","family":"Park","sequence":"additional","affiliation":[{"name":"Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Woo","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chungnam National University School of Medicine, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Sun","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Pathology, Chungnam National University School of Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-3450","authenticated-orcid":false,"given":"Heon Jong","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Chungnam National University School of Medicine, Chungnam National University Sejong Hospital, Sejong, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018.","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE \u2013 5-a population-based study.","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2012.12.023","article-title":"Transabdominal cardiophrenic lymph node dissection (CPLND) via incised diaphragm replace conventional video-assisted thoracic surgery for cytoreductive surgery in advanced ovarian cancer.","volume":"129","author":"Yoo","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO).","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(18)30566-7","article-title":"Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.","volume":"19","author":"Vergote","year":"2018","journal-title":"Lancet Oncol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1093\/jjco\/hyz071","article-title":"Phase I\/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer.","volume":"49","author":"Yoo","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1245\/s10434-011-1830-0","article-title":"Is neo-adjuvant chemotherapy a \u201cwaiver\u201d of extensive upper abdominal surgery in advanced epithelial ovarian cancer?","volume":"18","author":"Kang","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ygyno.2016.09.002","article-title":"Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.","volume":"143","author":"Melamed","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3390\/cancers13040626","article-title":"Emerging trends in neoadjuvant chemotherapy for ovarian cancer.","volume":"13","author":"Patel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.3802\/jgo.2019.30.e113","article-title":"Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study.","volume":"30","author":"Machida","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1758834014544891","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy.","volume":"6","author":"Sato","year":"2014","journal-title":"Ther Adv Med Oncol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","article-title":"Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).","volume":"28","author":"McCluggage","year":"2015","journal-title":"Mod Pathol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.","volume":"33","author":"Bohm","year":"2015","journal-title":"J Clin Oncol"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data.","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC).","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.humpath.2006.12.008","article-title":"Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer.","volume":"38","author":"Sassen","year":"2007","journal-title":"Hum Pathol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/ijgc-00009577-200303000-00004","article-title":"Distant metastases in ovarian carcinoma.","volume":"13","author":"Cormio","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.22919","article-title":"Metastatic patterns at autopsy in patients with ovarian carcinoma.","volume":"110","author":"Guth","year":"2007","journal-title":"Cancer"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.ygyno.2018.06.022","article-title":"Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.","volume":"150","author":"Deng","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.3802\/jgo.2017.28.e73","article-title":"External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/his.13399","article-title":"The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.","volume":"72","author":"Singh","year":"2018","journal-title":"Histopathology"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(06)70939-1","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer.","volume":"7","author":"Tan","year":"2006","journal-title":"Lancet Oncol"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.suronc.2020.03.001","article-title":"Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.","volume":"34","author":"Barrington","year":"2020","journal-title":"Surg Oncol"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fonc.2019.00778","article-title":"Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: the prognostic role of omental and ovarian residual disease.","volume":"9","author":"Santoro","year":"2019","journal-title":"Front Oncol"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/aogs.13814","article-title":"CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer.","volume":"99","author":"Kessous","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/IGC.0000000000000434","article-title":"The impact of percent reduction in CA-125 levels on prediction of the extent of interval cytoreduction and outcome in patients with advanced-stage cancer of mullerian origin treated with neoadjuvant chemotherapy.","volume":"25","author":"Mahdi","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1757-2215-6-31","article-title":"Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.","volume":"6","author":"Xu","year":"2013","journal-title":"J Ovarian Res"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2006.07.027","article-title":"CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.","volume":"104","author":"Juretzka","year":"2007","journal-title":"Gynecol Oncol"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/gyno.2000.5749","article-title":"The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.","volume":"77","author":"Chi","year":"2000","journal-title":"Gynecol Oncol"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/annonc\/mdi012","article-title":"Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?","volume":"16","author":"Crawford","year":"2005","journal-title":"Ann Oncol"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1200\/JCO.2005.04.7373","article-title":"Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.","volume":"24","author":"Markman","year":"2006","journal-title":"J Clin Oncol"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2006.02.024","article-title":"Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.","volume":"103","author":"Markman","year":"2006","journal-title":"Gynecol Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040487","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:34:14Z","timestamp":1746318854000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":36,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040487","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}